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Abstract
Background: 59-deoxy-59-methylthioadenosine (MTA) is an endogenous compound produced through the metabolism of
polyamines. The therapeutic potential of MTA has been assayed mainly in liver diseases and, more recently, in animal
models of multiple sclerosis. The aim of this study was to determine the neuroprotective effect of this molecule in vitro and
to assess whether MTA can cross the blood brain barrier (BBB) in order to also analyze its potential neuroprotective efficacy
in vivo.
Methods: Neuroprotection was assessed in vitro using models of excitotoxicity in primary neurons, mixed astrocyte-neuron
and primary oligodendrocyte cultures. The capacity of MTA to cross the BBB was measured in an artificial membrane assay
and using an in vitro cell model. Finally, in vivo tests were performed in models of hypoxic brain damage, Parkinson’s disease
and epilepsy.
Results: MTA displays a wide array of neuroprotective activities against different insults in vitro. While the data from the two
complementary approaches adopted indicate that MTA is likely to cross the BBB, the in vivo data showed that MTA may
provide therapeutic benefits in specific circumstances. Whereas MTA reduced the neuronal cell death in pilocarpine-induced
status epilepticus and the size of the lesion in global but not focal ischemic brain damage, it was ineffective in preserving
dopaminergic neurons of the substantia nigra in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-mice model.
However, in this model of Parkinson’s disease the combined administration of MTA and an A2A adenosine receptor
antagonist did produce significant neuroprotection in this brain region.
Conclusion: MTA may potentially offer therapeutic neuroprotection.
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Introduction
The sulfur-containing nucleoside 59-deoxy-59-methylthioadeno-
sine (MTA, CAS 2457-80-9) is produced from S-adenosylmethi-
onine during the synthesis of the polyamines spermine and
spermidine [1], and it acts as a potent inhibitor of polyamine
biosynthesis. MTA is metabolized by MTA-phosphorylase to yield
5-methylthioribose-1-phosphate and adenine, a crucial step in the
methionine and purine salvage pathways, respectively. The
potential of this natural compound as a therapeutic agent was
first demonstrated in experimental models of acute and chronic
liver damage, and liver carcinogenesis, for which high doses were
used without producing any significant toxicity [2–3]. More
recently, MTA was proved to have a remarkable immunomod-
ulatory activity in animal models of neuroinflammation, such as
experimental autoimmune encephalomyelitis (EAE) [4]. In this
model, when MTA was compared with other currently approved
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therapies for multiple sclerosis (MS), it was more effective and
better suited for combination therapy [5].
The effects of inhibiting polyamine metabolism on brain
function have not been addressed extensively, nor have the direct
actions of MTA in the central nervous system (CNS) been
investigated in detail. MTA was shown to have mixed effects on
nerve growth factor (NGF)-regulated survival and protein phos-
phorylation in sympathetic neurons isolated from chick embryos,
whereby MTA selectively blocked the NGF- but not high
K+-mediated survival of neurons [6]. By assessing the changes in
protein phosphorylation and methylation some early molecular
events involved in NGF-mediated neuronal survival were seen to
differ from those associated with high K+-mediated survival.
Accordingly, MTA can block the NGF- but not the high
K+-mediated decrease in phosphorylated p70, thereby showing
that neural survival may involve distinct protein phosphorylation
pathways, although these may later converge [6].
Clinical experiences with NGF suggest that neurotrophins or
compounds with neurotrophin-like actions might be useful to
develop new strategies to treat Parkinson’s disease (PD) and/or
other neurodegenerative disorders [7]. In the light of the anti-
inflammatory effects of MTA, we set out to assess whether MTA is
a neuroprotective agent in vitro and in animal models of diseases
involving neuroinflammation, oxidative stress and excitotoxic
damage, such as stroke, PD and epilepsy.
Methods
Animals
Experiments were performed in accordance with the Guidelines
for the Care and Use of Mammals in Neuroscience and Behavioral
Research (2003), and they were approved by the Ethical
Committee for Animal Testing of the University of Navarra,
University of Basque Country, University of Castilla la Mancha
and University of Michigan, and by the Department of Health of
the Government of Navarra. The animals were maintained in
positive pressure-ventilated racks at 2561u on a 12 h light/dark
cycle and fed ad libitum.
Primary cultures
Primary rat oligodendrocyte (OL) cultures were derived from
the optic nerve of 12-day-old Sprague-Dawley rats, as described
previously [8]. Cells were seeded onto 12 mm diameter coverslips
coated with poly-D-lysine (10 mg/ml) in 24-well plates at a density
of 56103 cells per well. The cells were maintained at 37uC in 5%
CO2 and in a chemically defined medium [8]. After 2–4 days in
vitro, the cultures were composed of at least 98% O4/
galactocerebroside-positive (O4/GalC) cells, while the majority
of the remaining cells were stained with antibodies against glial
fibrillary acidic protein (GFAP). No A2B5+ or microglial cells were
detected in these cultures [9].
Primary cultures of rat brain cortical neurons were prepared
essentially as described previously [10]. The fronto-lateral cortical
lobes were dissected out of Sprague-Dawley embryonic day 17
fetuses and they were dissociated mechanically in Hanks’ balanced
solution. After centrifugation at 8006g for 5 min, the cells were
resuspended in serum-free Neurobasal medium (GIBCO) supple-
mented with B27 (GIBCO) containing 2 mM L-glutamine,
penicillin (20 units/ml) and streptomycin (5 mg/ml), and they
were plated onto poly-L-lysine-coated 24-well culture plates or on
poly-L-lysine-coated 6-well culture plates. The cells were main-
tained at 37uC in a 95% air and 5% CO2 atmosphere of saturated
humidity, and the cortical neurons were used for experiments after
7 days in vitro.
Finally, to prepare neuron-astrocyte co-cultures, neurons were
resuspended in B27 Neurobasal medium plus 10% of foetal bovine
serum (FBS) and then seeded onto a monolayer of astrocytes in 24-
well plates at a density of 1–26105 cells per well, the astrocytes
having been prepared beforehand, as described elsewhere [11].
One day later, the medium was replaced with B27-Neurobasal
plus 10% FBS medium, and the cells were maintained at 37uC in
5% CO2. The cultures were used 8–9 days after plating. Neurons
and astrocytes were identified with antibodies against microtubule-
associated protein-2 and GFAP, respectively.
To assay N-methyl–D-aspartate (NMDA) excitotoxicity, prima-
ry cultures were seeded in 24-well plates at 156104 cells/well,
cultured for 7 days in vitro, and treated for different times with the
vehicle alone (dimethyl sulfoxide (DMSO) 1%), NMDA (300 mM),
NMDA (300 mM) + MTA (250 mM) or NMDA (300 mM) + MK-
801, a NMDA receptor antagonist (10 mM). The supernatants
were collected and the cells were washed with PBS and lysed with
0.9% Triton X-100 (v/v) in saline. Caspase 3 activity was
measured in these lysates one hour after the NMDA addition.
For a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) assays in primary rat OLs, cells were pre-incubated with
MTA (100 mM and 300 mM) for 15 min and then exposed to
AMPA (10 mM) for an additional period of 15 min. Cell viability
was assessed with calcein-AM (Invitrogen) 24 h after application of
AMPA, and the number of survival cells on each coverslip was
detected by their fluorescence (515 nm filter) and quantified.
Oxygen-glucose deprivation (OGD) in primary rat
cultures
Ischemic damage was induced by incubating cell cultures for
1 h in a hyperbaric chamber in a nitrogen-saturated buffer
containing: 130 mM NaCl, 5.4 mM KCl, 0.1323 mM CaCl2,
0.26 mM NaHCO3, 0.8 mM MgCl2, 1.18 mM NaH2PO4,
10 mM sucrose (OGD plus sucrose) and iodoacetate (IAA, 20 or
50 mM). IAA is a glycolytic blocker typically used in OGD
experiments to simulate ischemic conditions [12]. After the insult,
the cells were incubated under normoxic conditions for an
additional 24 h in the presence of glucose but in the absence of
IAA. Distinct reagents were added during ischemia to evaluate
their neuroprotective activity by assessing cell viability and cell
death in the cultures.
Cell viability
LDH assay. The cell status was assessed by measuring the
release of lactate dehydrogenase (LDH) from dead cells. LDH was
measured spectrophotometrically at 490 nm on a 96-well plate
reader using the Cytotox 96 Kit according to the manufacturer’s
instructions (Promega). The LDH release was defined by the ratio
of LDH released to the total LDH present in the cell at the
beginning of the treatment.
Caspase 3 activity. Cortical neurons, or mixed cortical
neurons and glia, were seeded in poly-L-lysine-coated 6-well
culture plates during 7 days in vitro before start the set of
experiments. In co-treatment conditions cells were treated for 1 h
with NMDA (300 mM) alone or in the presence of MTA (100, 250
and 500 mM) or MK-801 (10 mM). In pre-treatment conditions
MTA or MK-801 were added 15 minutes before NMDA. To
determine caspase 3 activity, the cells were washed twice with cold
PBS and lysed in buffer containing 100 mM HEPES, 5 mM
dithiothreitol (DTT), 5 mM ethylene glycol tetra-acetic acid
(EGTA), 0.04% Nonidet P-40 and 20% glycerol (pH 7.4). The
extracts were then centrifuged at 5,0006g for 10 min at 4uC and
the protein content was determined by the BCA protein assay. Cell
extracts (40 mg of protein) were incubated for 1 h at 37uC in a
MTA Neuroprotection
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reaction buffer (25 mM HEPES, 10% sucrose, 0.1% CHAPS,
10 mM DTT) containing 50 mM of the fluorescence substrate, Z-
DEVD-AFC. Cleavage of the AFC fluorophore was determined in
a spectrofluorometer at an excitation wavelength of 400 nm and
the fluorescence emitted was detected at a wavelength of 505 nm.
Caspase 3 activity was expressed as units of fluorescence per
milligram of protein per hour.
Animal models of disease
Focal and global ischemia models in rats. Male Wistar
rats (270-300 g; Harlan) were subjected to transient focal ischemia
for 90 min by producing right middle cerebral artery occlusion
(MCAO) as described previously [13], followed by reperfusion for
3 days and MTA treatment (30 mg/kg, intraperitoneally –i.p.-
twice daily) starting 30 min after the onset of ischemia (n = 5 in
each experimental group). Cerebral blood flow was monitored
transcranially with a laser Doppler flowmeter (Perimed) and the
infarct volume was assessed by 2,3,5-triphenyltetrazolium chloride
(TTC) staining. Transient forebrain ischemia was induced as
described elsewhere [14], by occluding the vertebral and common
carotid arteries (4VO) for 10 min, followed by reperfusion for 7
days and MTA treatment (as above) starting 30 min after the onset
of ischemia (n = 5 in vehicle group; n = 6 in the vehicle group).
The effectiveness of the treatment was assessed by using fluoro-
Jade C staining to measure the levels of degenerated neurons in
the CA1 region of the hippocampal formation.
Status epilepticus rat model. Young adult (175–200 g)
male Sprague-Dawley rats from Charles River (Wilmington, MA,
US) were divided into four MTA treatment groups, with 9–11 rats
per group. In group A, rats were subjected to pilocarpine-induced
status epilepticus (SE) as described previously [15]. Following
90 min of continuous seizure activity, SE was stopped by
administering a single dose of diazepam (10 mg/kg). The rats
were then injected daily for 3 days with either the vehicle alone
(2% DMSO in H2O), injecting a volume of body weight x 3.3 (a
similar volume as for the MTA treated groups), or MTA (30 mg/
kg). Rats were euthanized on day 4 after SE under anesthesia by
transcardiac perfusion with 4% paraformaldehyde (PFA) in
phosphate-buffered saline. The brains were removed, postfixed
in 4% PFA, cryoprotected in 30% sucrose, frozen, and sectioned
for histology. In group B, the rats received the same treatment as
those in group A (vehicle or MTA 30 mg/kg) except that the rats
were perfused on day 30 after SE and a 0,37% sulphide fixative
was used for subsequent Timm staining. In group C, the rats were
only treated with MTA (30 mg/kg) or the vehicle for 2 days and
on the third day, the rats were again subjected to pilocarpine-
induced SE. The animals were then treated once daily with with
MTA (30 mg/kg) or vehicle for a further 3 days, and they were
anesthetized and euthanized 4 days after SE. In group D, the rats
received the same treatment as group C (vehicle or MTA 30 mg/
kg) except that they were euthanized 30 days after SE and a 0,37%
suphide fixative was also used foe subsequent Timm staining. The
brain sections obtained from these animals were stained with
cresyl violet (Nissl), Timm Stain or by immunohistochemistry for
Neu N.
MPTP mouse model of Parkinson’s disease. 12-week-old
male C57Bl mice from Charles River (Barcelona, Spain) were
injected i.p. with 30 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP, Sigma-Aldrich) on five consecutive days.
Subsequently, MTA (30 mg/kg) and/or the A2A adenosine
receptor (A2AR, 10 mg/kg) antagonist, MSX-3 (Sigma-Aldrich),
was administered one day before starting MPTP treatment and
1 h after each MPTP injection (n = 6 in each experimental group).
We used mice in the MPTP model because rats are resistant to
systemic MPTP administration and thus, the rat MPTP model
requires stereotaxic MPTP injection directly into the nigrostriatal
fibers. Systemic administration destroys adrenergic neurons of
sympathetic ganglia but it is not toxic in the CNS.
Tissue processing
Animals were anesthetized with an overdose of 10% chloral
hydrate (Panreac, Barcelona, Spain) in distilled water and perfused
transcardially with a fixative solution containing 4% PFA (Merck,
Darmstadt, Germany) in 0.125 M PBS. The brain of each animal
was removed and cryoprotected for 48 h in PBS containing 20%
glycerin and 2% DMSO. All solutions used for perfusion and
cryoprotection were treated with 0.1% diethylpyrocarbonate
(DEPC) and autoclaved prior to use. Frozen coronal microtome
sections (50 mm thick) were collected in cryoprotective solution
and stored at 280u.
Fluoro-Jade C staining
Fluoro-Jade C (Chemicon, Millipore) was used to visualize
dying neurons in 10 mm frozen coronal sections pretreated for
15 min with 0.06% KMnO4. After washing in distilled water, the
sections were incubated for 30 min in fluoro-Jade (0.0001% in
0.1% acetic acid), washed again, dried, cleared in xylene and
coverslipped with DPX. Serial photomicrographs of the hippo-
campal CA1 regions were collected at random with a digital
camera using a 206objective. Cells were counted in the right and
left hemispheres of each stained section, examining four sections
from each experiment.
Nissl and Timm staining
Mouse and rat coronal sections were mounted on glass slides in
a 0.2% solution of gelatin in 0.05 M Trizma base [pH 7.6]
(Sigma-Aldrich), and they were dried overnight at room temper-
ature (RT). Following incubation with a mixture of chloroform
and ethanol for 1 h, the sections were hydrated serially in 100%,
96%, 80% and 50% alcohol, and rinsed twice in distilled water for
2 min. Nissl staining was performed for 2 min with a solution
containing 8.7 mM thionine (Sigma-Aldrich), 30 mM NaOH
(Sigma-Aldrich) and 1.2% ethanol. The sections were then washed
with distilled water, dehydrated with successive 2 min incubations
in increasing concentrations of alcohol (70, 96 and 100%), cleared
in xylene for 6 min and cover slipped with DPX (BDH
Chemicals). For Timm staining, sections were mounted onto
superfrost plus slides (Fisher, Pittsburgh, PA) and then dehydrated,
rehydrated and placed in a staining solution containing gum
arabic, citrate, hydroquinone and silver nitrate and incubated at
26uC. After development of the stain, sections were washed,
dehydrated and delipidated in graded ethanols and xylenes, and
coverslipped. To evaluate sprouting of the zinc-containing mossy
fibers in the dentate gyrus inner molecular layer, Timm-stained
sections were analyzed by an examiner blinded to experimental
condition. A minimum of 5 sections, spanning the rostral, mid,
and caudal dentate gyrus were examined by densitometry. Twelve
samples of pixel density/section were measured in the inner
molecular layer using NIH ImageJ, 5 from the lower blade, 5 from
the upper blade and 2 from the apex. The average background
level (mean of 12 samples/section) was subtracted and a mean
pixel density calculated for each animal (n = 4–5/group).
Immunohistochemistry
Free-floating coronal brain sections were washed sequentially
with PBS, treated with 0.03% H2O2 in methanol for 40 min to
block endogenous peroxidase activity and washed a further three
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times with PBS. Non-specific binding was blocked by incubating
for 40 min at RT in a blocking solution: 4% normal goat serum,
0.05% Triton X-100 and 4% BSA in PBS. The sections were
incubated overnight at 4u with a specific anti-tyrosine hydroxylase
(TH) antibody (1:500; clone 16 T-2928 Sigma-Aldrich) and with
mouse monoclonal anti-NeuN (1:1000; Millipore, Billerica, MA,
US), both diluted in blocking solution. After washing with PBS
several times, the sections were incubated for 2 h at RT with the
corresponding secondary antibody diluted in blocking solution, a
biotinylated goat anti-rabbit or biotinylated goat anti-mouse
(1:300; Jackson ImmunoResearch Laboratories, West Grove,
PA). After washing several times with PBS, the sections were
incubated for 90 min with streptavidin-HRP (1:4000; Sigma-
Aldrich) and the bound peroxidase activity was visualized by
incubation with 0.05% diaminobenzidine (Sigma-Aldrich) in
0.03% H2O2/Tris-HCl [pH 7.6]. The sections were mounted
on glass slides in a 0.2% solution of gelatin in 0.05 M Tris
[pH 7.6] (Sigma-Aldrich), dried overnight and dehydrated in
toluene for 12 min before they were coverslipped with DPX (BDH
Chemicals, Poole, UK). The usual tests to control for specificity
were performed in parallel.
Stereological counting
In the pilocarpine SE model, NeuN-positive cells in the
hippocampal CA1 and CA3 regions were counted stereologically
in the 30-day survival groups. The regions of interest were outlined
at low magnification (46) and the NeuN-labeled cells were
counted at 1006 using the optical fractionator technique
(StereoInvestigator software, MicroBrightField) with systematic
random sampling of every 6th section in a series of 50 mm coronal
sections through the hippocampus.
In the MPTP mouse model, the substantia nigra pars compacta
(SNpc) volume was estimated according to the Cavalieri method.
The number of TH-positive neurons was established through
unbiased design-based stereology, performed blind to the genotype
and group. All stereological counting was performed with the
newCAST Visiopharm (Denmark) software using an Olympus
Bx61 microscope equipped with a camera (model DP71,
Olympus) and a stage connected to a xyz stepper (model
H101BX, PRIOR). Specifically, we used the dissector counting
procedure in six SNpc coronal sections (50 mm thick) per animal,
equally-spaced and covering the entire rostro-caudal extent of the
nucleus.
The reference volume was calculated according to Cavalieri
principles from images obtained with a 26objective using a point
count array [16]. The cross-sectional area of the nucleus was
measured and the reference volume (Vr) for the entire nucleus was
estimated using the following equation:
Vr~T
a
p
X
i~1
Pi
where T is the thickness of the sections, a/p is the area of each
Figure 1. Effect of MTA under NMDA excitotoxicity. Effect of MTA co-treatment (a) or MTA pre-treatment (b) on NMDA-induced caspase 3
activation in rat pure primary neuronal cultures. Effect of MTA co-treatment (c) or MTA pre-treatment (d) on NMDA-induced caspase 3 activation in rat
mixed astrocyte-neuron cultures. Caspase 3 activity (units of fluorescence per milligram of protein per hour) was determined in cells treated with
300 mM NMDA, in the presence or absence of MTA (panels a and b: 100, 250 and 500 mM; panels c and d: 250 mM) or 10 mM MK-801 (MK; NMDA
receptor antagonist). The results are expressed as the mean 6 SEM of at least four independent experiments performed in triplicate: *p,0.05,
**p,0.01***p,0.001 compared with cells treated with NMDA;# p,0.05,## p,0.01,### p,0.001 compared with vehicle cells. One-way analysis
of variance (ANOVA) and Bonferroni’s t-test for multiple comparisons.
doi:10.1371/journal.pone.0090671.g001
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point and Pi is the number of points that landed within the area.
The region of interest to estimate the area was outlined at low
magnification (46), and the number of labeled neurons was
calculated under 1006 magnification (with oil immersion) using
randomized meander sampling and the optical dissector methods.
The optical dissector height was 12 mm. The sampling area and
the counting frame were 3% and 3,025.6 mm2, and unbiased
counting was performed by an experimenter blind to the
treatments. Total Nissl stained neurons (N) were calculated using
the following formula:
N~
X
Q{
t
h
1
asf
1
ssf
where SQ2 is the total number of particles counted, t is the mean
section thickness, h is the height of the optical dissector, asf is the
area sampling fraction, and ssf is the section sampling fraction.
Neuronal density (D) was determined by the following formula:
D = N/Vr.
Figure 2. Effect of MTA under OGD and AMPA excitotoxicity. Panels a and b: the effect of APV (100 mM) or MTA in OGD conditions in rat
mixed cultures of neurons and astrocytes. Cell death was expressed as the LDH activity at the beginning of any treatment: *p,0.05 compared to IAA-
treated cells;# p,0.05 compared to control; ** p,0.01 compared to IAA-treated cells;## p,0.01 compared to control. c) primary oligodendrocytes
derived from rat optic nerve subjected to AMPA excitotoxicity (10 mM and 100 mM) in which cell death was measured with calcein-AM, as indicated in
Methods. *p,0.05 compared with cells treated with AMPA (Unpaired t-test). Values represent the average 6 SEM and were obtained from at least
three independent experiments performed in duplicates.
doi:10.1371/journal.pone.0090671.g002
Table 1. Effective permeability (Pe) values in the PAMPA assay and in the in vitro model of BBB.
Compound Model % Membrane retention Pe x 1026 (cm/s)
Methylthioadenosine (MTA) PAMPA 0 0.15*
Carbamazepine PAMPA 0.5 11.5
Propanolol PAMPA 30.2 10.3
Methylthioadenosine (MTA) BBB ----- 4.5
Transferrin BBB ----- 8.2
Apo E BBB ----- 2.2
*transport confirmed by HPLC-MS.
doi:10.1371/journal.pone.0090671.t001
MTA Neuroprotection
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Parallel artificial membrane permeability assay (PAMPA)
The PAMPA assay was used to determine the capacity of
compounds to cross a blood brain barrier (BBB) model by passive
diffusion, measuring the effective permeability of the compounds
at an initial concentration of 200 mM. The buffer solution was
prepared from a concentrated commercial solution (Pion, Billerica,
MA, US) according to the manufacturer’s instructions and the pH
was adjusted to 7.4 with 0.5 M NaOH. The compound of interest
was dissolved in the buffer solution (200 mM), the PAMPA
sandwich was separated and the donor well was filled with 195 mL
of the compound of interest. The acceptor plate and donor plate
were brought together, with the underside of the membrane in
contact with the buffer. An 4 mL aliquot of the phospholipid
mixture (20 mg/ml) in dodecane was added to the filter of each
well, and then 200 mL of buffer solution was added to each
acceptor well. The plate was covered and incubated for 4 h at RT
in a saturated humidity atmosphere with agitation and with 25 mm
of an unstirred water layer in the Gut-Box (Pion). After 4 h, a
150 mL/well sample from the donor plate and a 150 mL/well
sample from the acceptor plate were transferred to HPLC vials.
Then, 100 mL from acceptor well, 5 mL from the donor well and
5 mL from the t0 samples were injected into an HPLC reverse-
phase symmetry C18 column (150 mm64.6 mm65 mm, 100 A˚;
Waters). Transport was confirmed by HPLC mass spectrometry
and matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) spectrometry to ensure the compound had
maintained its integrity. The phospholipid mixture used was a
porcine polar brain lipid extract composed of 12.6% phosphati-
dylcholine (PC), 33.1% phosphatidylethanolamine (PE), 18.5%
phosphatidylserine (PS), 4.1% phosphatidylinositol (PI), 0.8%
phosphatidic acid and 30.9% of other compounds.
In vitro model of transport across the BBB
A in vitro cell model of BBB permeability was established using a
co-culture of bovine-brain endothelial cells (BBECs) and newborn
rat astrocytes. The cells were first cultured in 24-well (TranswellR)
permeable supports with a surface area of 0.33 cm2 and a pore
size of 0.4 mm (Corning), the upper surface of which was coated
with collagen type IV and fibronectin. The inserts were then
placed upside down in a large petri dish, and 40 mL of a
suspension (containing approximately 45,000 astrocytes) was
placed on the bottom of each filter. The petri dish was incubated
at 37uC for 1 h, and 40 mL of fresh DMEM+S was added to the
bottom of each filter every 15 min. The inserts were then
Figure 3. Effect of MTA on brain ischemia. (a) Representative TTC stained sections of vehicle and MTA treated animals (30 mg/kg/twice daily,
i.p.) 3 days after the induction of transient focal ischemia. Histogram (right) showing the infarct volume calculated from TTC stained slices in vehicle-
and MTA-treated rats (n = 5 in each group). b) Representative microphotographs of Fluoro Jade C staining after rat transient forebrain ischemia (n = 5
in the vehicle group; n = 6 in the MTA-treated group). MTA (30 mg/kg) was administered 30 min after triggering ischemia. Quantification of Fluoro
Jade positive cells per mm length of CA1 pyramidal layer (right). The data represents the mean 6 SEM: **p,0.01 compared to the vehicle (Student
t-test). Scale bar 100 mm.
doi:10.1371/journal.pone.0090671.g003
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transferred back to the plate and incubated at 37uC in 5% CO2 for
3 d. Then, 2 h before seeding the BBECs, the medium was
replaced by DMEM+S supplemented with 125 mg/mL heparin
and 2 h later, the cells were seeded onto the inserts (45,000 cells
per filter). The plate was incubated at 37uC in 5% CO2 for 3 more
days, after which the medium was replaced by DMEM+S
supplemented with cyclic adenosine monophosphate (cAMP) and
RO-20-1724, and kept at 37uC in 5% CO2. On day 8 of the co-
culture, the transendothelial electrical resistance (TEER) was
measured to determine whether the system was ready for transport
studies. To validate the maturity of the model, permeability assays
with lucifer yellow (LY) were performed in parallel as a marker of
the integrity of the in vitro barrier. During the permeability assay,
the samples were co-incubated with LY (20 mM) to assess the
integrity of the cellular monolayer during the assay.
Data analysis
The data in the graphs are presented as the mean 6 SEM and
statistical analysis was performed with SPSS 18.0 software.
Significance was tested with a Student t-test or one-way ANOVA
test followed by a LSD, Bonferroni or Tukey HSD test as a post
hoc. Significant differences were considered when p,0.05.
Results
MTA as a neuroprotective agent for neural cells cultured
in vitro
To evaluate the neuroprotective potential of MTA at the
cellular level, various cell models and noxious insults were used.
Excitotoxicity seems to be involved in the pathogenesis of epilepsy,
brain ischemia and other neurodegenerative diseases [17].
Accordingly, the role of MTA in promoting the survival of
neurons treated with NMDA was tested. The survival of rat
neurons in culture (99% purity) when exposed to toxic concen-
trations of NMDA (up to 500 mM) was not enhanced by co-
treatment with MTA (as measured by caspase 3 activity: Fig. 1a).
However, when neuronal cultures were pre-treated with MTA,
caspase 3 activity decreased significantly at the different concen-
tration tested (Figure 1b). When mixed cultures (neurons and
astrocytes) were pre- or co-treated with MTA, we found that
caspase 3 activation induced by NMDA reverted to basal levels, an
effect also produced by the ionotropic glutamate receptor
antagonist, MK-801 (Fig. 1c and 1d). These results suggest a key
role for astrocytes in mediating some of the beneficial effects of
MTA. The role of MTA in promoting survival was also tested in
mixed rat neuronal-astrocyte cultures subjected to oxygen-glucose
deprivation induced by IAA. At the two doses of IAA used (20 and
50 mM), protection afforded by 10 mM or 100 mM MTA was
significant and similar to that provided by 100 mM of the NMDA
receptor antagonist, (2R)-amino-5-phosphonovaleric acid (APV:
Fig. 2 a–b). Interestingly, a supramaximal dose of MTA (1 mM)
was neither protective nor did it lead to greater damage than
OGD itself, suggesting that an excess of the compound does not
exacerbate toxicity. Primary rat OL cultures were also treated with
toxic doses of AMPA and cell activity was measured with calcein-
AM, a probe that provides robust data in these oligodendrocyte
cultures. It should be noted that OLs are more sensitive to AMPA
than to NMDA excitotoxicity [18]. MTA fully protected OLs
against AMPA toxicity (Figure 2c). These results indicate that
MTA may protect neurons and oligodendrocytes from excitotoxic
insults and that excess MTA does not enhance toxicity of neurons
in pure or mixed neuron-glia cultures.
MTA neuroprotection in animal models of ischemia,
neurodegeneration and excitotoxicity
To evaluate the potential neuroprotection offered by MTA, we
assessed its effects in animal models of brain diseases that involve
inflammation and excitotoxicity. Any drug aimed at targeting
neural cells in the CNS must cross the BBB. Therefore, we first
measured the ability of MTA to cross the BBB in vitro using a
PAMPA and an in vitro cell model of the BBB. In the PAMPA
model, we found that MTA could cross the BBB by passive
Figure 4. MTA effects in chronic pilocarpine-induced status epilepticus (SE). a–f: Representative images of Neu N immunoreactivity in the
hippocampus are shown 3 days after sham treatment (a) or pilocarpine-induced SE (b, c), or 30 days after SE (d–f). MTA (30 mg/kg) was administered
pre-SE (d) or post-SE (c,f) induction. Cell loss is already apparent by 3 days (arrows in b) and is marked by 30 days (e) after SE, but it appears
attenuated in MTA-treated animals at both timepoints (c,d,f). g–h) Bar plots show quantification of NeuN-positive cells in CA3(g) or CA1(h) 30 days
after SE in animals pre-treated with MTA. The data represent the mean 6 SEM. *p,0.05; **p,0.001; ANOVA with Tukey HSD post –hoc test.
doi:10.1371/journal.pone.0090671.g004
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diffusion with a low to intermediate effective permeability as
compared to the reference compounds, propranolol and carba-
mazepine (Table 1). Membrane retention of MTA was negligible,
whereas it was significant for propranolol (30%: Table 1). The
potential of MTA to cross the BBB was confirmed in an in vitro cell
model, in which MTA displayed an effective permeability
coefficient (Pe = 4.561026 cm/s) in between that of the control
compounds, transferrin (Pe = 8.261026 cm/s) and ApoE (Pe =
2.261026 cm/s: Table 1).
The neuroprotective effect of MTA was first evaluated in the rat
transient MCAO model of focal brain ischemia. In this model, rats
treated with MTA did not show any reduction in the volume of the
infarct area compared with those treated with the vehicle alone
(Fig. 3a). By contrast, MTA afforded protection to neurons
following global brain ischemia, as fewer cells in the hippocampal
CA1 region were stained with Fluoro Jade C following MTA
administration (110620 cells/mm) compared to those in untreat-
ed animals (180610 cells/mm: Fig. 3b).
Temporal lobe epilepsy is associated with substantial neuronal
loss in the hippocampus due to excitotoxicity and thus, we
examined the effects of MTA (30 mg/kg/day) in the pilocarpine
model of SE. Accordingly, we administered MTA for 5 days to one
group of rats, beginning 2 days before SE (pre-SE MTA), while
another group was given MTA for 3 days beginning at the
termination of SE (post-SE MTA). Subsequently, brain sections
were examined for cell loss either 3-5 days (early time point) or 30
days (late time point) after SE. As controls, one group received the
vehicle alone instead of MTA and underwent SE, while a second
control group received MTA and saline instead of pilocarpine (No
SE). The SE model caused neuronal loss in the hippocampus,
mainly in the CA1 and CA3 regions, and dentate gyrus, whereby
these cell layers became thinner (Figure 4). The alterations in
Figure 5. Effect of MTA and A2AR antagonists in an acute mouse model of PD. The effect of MTA (30 mg/kg), MSX-3 (9 mg/kg) or both in
combination on the survival of dopaminergic neurons (TH+ cells) within the substantia nigra of the brain of mice treated with MPTP. a) Representative
images of the neurodegeneration of dopaminergic cells in the different groups. b) Stereological counts of TH+ neurons in control and drug-treated
animals (n = 6 per group). The data represent the mean6SEM: *p,0.05 comparing with the MPTP group; # p,0.05 comparing with the control
group (One-way ANOVA, LSD test as a post-hoc). Scale bar: 50 mm.
doi:10.1371/journal.pone.0090671.g005
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hippocampal structure displayed by these animals were more
evident 30 days after SE (Fig. 4e, arrows). The administration of
MTA either before or after SE reduced the neurodegeneration
and neuronal loss observed in the aforementioned hippocampal
areas at both the early and late time points analyzed, as witnessed
by NeuN immunoreactivity (Fig. 4c, f). Indeed, 30 days after SE
there were significant reductions in the neuronal loss in the CA3
and CA1 hippocampal areas of animals that received MTA prior
to SE, as quantified through the unbiased stereological counting of
NeuN-immunoreactive cells, althought they still showed significant
loss compared to sham animals (Fig. 4g,h). No difference in mossy
fiber sprouting was observed in either of the MTA treatment
groups studied (Figure S1).
In PD, the degeneration of dopaminergic neurons in the
substantia nigra is in part due to oxidative stress and excitotoxicity.
To assess whether MTA protects dopaminergic neurons from
oxidative stress, we used acute MPTP administration since this
neurotoxin produces in acute treatments very marked dopamine
nigral denervation and dopaminergic neuronal loss that can be
assessed by TH immunostaining (Fig. 5a). An A2A adenosine
receptor (A2AR) prodrug antagonist was also administered in this
model as several A2AR antagonists are undergoing clinical trials to
assess their capacity to alleviate the motor symptoms of PD and/or
to prevent levodopa-induced involuntary movements. As such,
MTA, the A2AR antagonist prodrug, MSX-3, or both were
injected 24 h before MPTP and, on the next 4 days MTA, MSX-3
or both were injected 1 h before administering MPTP. Neuro-
protection was quantified by unbiased stereological counting of
TH+ neurons in the substantia nigra, which highlighted the
neuroprotective trend of the individual treatments that was,
nevertheless, not statistically significant. However, the combined
treatment did lead to significant neuroprotection (Fig. 5b).
In summary, in vivo therapy with MTA in animal models of
brain damage may protect neurons from death depending on the
noxious stimulus and/or on combined administration with other
drugs.
Discussion
In this study we evaluated the ability of the natural metabolite
MTA to protect the CNS from damage in cellular and animal
models of neurological disease. Intermediate metabolism plays a
critical role in maintaining cell homeostasis and in the responses to
stress, as evident through the potentially beneficial anti-oxidant
properties of fumaric acid, an intermediate metabolite of the
Kreb’s cycle, [19]. Here, we report the differential neuroprotective
effects of MTA in different models of CNS disease.
In PD, apart from nigral neurodegeneration, extranigral
neuropathological changes occur that include an extensive a-
synuclein pathology, as well as neuroinflammatory responses in
specific brain regions ([20–21] for review). In normal circum-
stances, only a few T lymphocytes are found circulating in the
neuronal CNS parenchyma, reflecting their limited passage into
the brain. However, the release of proinflammatory cytokines by
microglia in PD-related conditions upregulates the expression of
intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion molecule-1 (VCAM-1) by endothelial cells of the BBB,
which are counter receptors for cell surface proteins in T cells and
monocytes [22]. Selective T cell infiltration of degenerative lesions
reflects the changes in the parenchymal milieu that resemble those
occurring in peripheral inflammatory lesions [23]. T lymphocytes
contribute to neurodegeneration by amplifying and exacerbating
ongoing inflammatory processes. Thus, both adaptive and innate
immune responses appear to play a pivotal role in the pathogenesis
of PD, providing a meaningful rationale for therapies that target
the immune system [21]. MTA has previously been shown to
provide benefits in animal models of MS, a disease that has a clear
neuroinflammatory component [5–6]. In our study, it does not
appear to protect against the neuroinflammation produced by
MPTP in the PD mouse model when tested alone. However, when
combined with an A2A adenosine receptor antagonist, MTA
therapy does result in neuroprotection, which is particularly
significant given that A2A adenosine receptor antagonists are
currently being assessed in clinical trials for the symptomatic
treatment of PD and the prevention of L-DOPA-induced
dyskinesias. Indeed, these molecules are not considered to protect
against the death of dopaminergic neurons in the course of PD.
However, we show here that the combination of these two
compounds, which individually are not efficacious, protects nigral
neurons exposed to MPTP from damage. The anti-PD effect of L-
DOPA, which is converted into dopamine, is exacerbated by A2A
receptor antagonists, as they decrease the negative adenosinergic
tone and affect the function of postsynaptic D2 dopamine
receptors. The protection provided by combined MTA and
MSX-3 treatment is achieved presynaptically and it probably
reflects the synergy between MTA-selective activities and the
blockade of A2A receptor signaling in the body of dopaminergic
neurons within the substantia nigra.
The results reported here also indicate that MTA produces a
marked preservation of CA1 and CA3 hippocampal neurons that
are sensitive to pilocarpine, thereby raising the possibility of using
MTA in the treatment of certain types of epilepsy. This hypothesis
is further supported by the protection afforded in the cells
subjected to excitotoxicity. Furthermore, we demonstrate the
therapeutic potential of MTA in some aspects of hypoxia, both in
cellular and animal models. MTA was effective in global ischemia
but it failed to reduce the infarct area in the MCAO model of focal
brain ischemia, two pathologically distinct events. While in focal
ischemia the main damage is provoked by necrosis in the
‘‘ischemic core’’, the global ischemia model diminishes blood flow
over the entire brain, provoking neuronal death in more
vulnerable areas, such as the CA1 of the hippocampus. These
differences in the mechanisms that provoke damage and the
distinct vulnerabilities of specific cell populations could explain the
different effects of MTA on focal and global cerebral ischemia.
The mechanisms by which MTA mediates cell protection are
complex and pleiotropic. The in vitro effects of therapies based on
this endogenous metabolite involve its anti-oxidant capabilities
[24], yet MTA is likely to have other effects in vivo as it influences
numerous events that regulate gene expression, cell proliferation
and differentiation, and apoptosis [2,4]. Accordingly, it is
reasonable to assume that an increased load of MTA alters
secondary metabolism and has an impact on mechanisms involved
in coping with oxidative stress, as well as on cell survival/death
[25]. Indeed, pharmacological manipulation of other endogenous
metabolite such as kynurenic acid concentrations can provide
neuroprotection against hypoxia-ischemia and NMDA lesions in
neonatal rats [26]. Kynurenic acid is one of the main products of
the kynurenine pathway that is produced from L-tryptophan. The
neuroprotective effect of this compound was first attributed to its
antagonistic action on ionotropic NMDA glutamate receptors,
although other mechanisms are also involved [27]. In fact, the
kynurenine metabolic pathway in human neurons was character-
ized to show that its association with neuroprotection depends on
the expression of key metabolic enzymes [28]. For instance, the
expression of picolinic carboxylase in primary and in some adult
neurons leads to production of the excitotoxic quinolinic acid,
whereas the lack of the enzyme in SK-N-SH cells allows the
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neuroprotectant picolinic acid to accumulate. Therefore, the
presence or absence of a single enzyme may lead to the production
of a neuroprotective or neurotoxic metabolite.
It should be noted that it appears to be safe to administer MTA
exogenously to both animals and cell lines. In fact, a good safety
record has already been shown in phase I studies reported in 1984
[29]. The treatment of CNS diseases requires drugs to enter the
brain by crossing the BBB. Given the data from the BBB models
used here, it would appear that oral administration of MTA would
enhance its concentration in the brain. In conclusion, MTA
appears to be a safe candidate to offer neuroprotection and to
produce benefits in a variety of neurological diseases, making it
potentially suitable to enter into clinical trials.
Supporting Information
Figure S1 No effect of MTA treatment on mossy fiber
sprouting after pilocarpine-induced status epilepticus
(SE). a-c) Representative Timm-stained sections 30 days after SE
from a vehicle-treated control (a) and animals that received MTA
(30 mg/kg) post –SE (b) or pre-SE (c) show no difference in mossy
fiber sprouting. d, e) Quantification of Timm staining density in
the inner molecular layer at 30 d after SE showed no differences
between groups (d, p = 0.84; e, p = 0.86; Student t-test). n = 4-5/
condition. The data represent the mean 6 SEM.
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